

1                    **Decreased brain pH correlated with progression of Alzheimer’s disease**  
2                    **neuropathology: a systematic review and meta-analyses of postmortem studies**

3  
4                    Hideo Hagihara, Ph.D.<sup>1\*</sup> and Tsuyoshi Miyakawa, Ph.D.<sup>1\*</sup>

5  
6                    <sup>1</sup>Division of Systems Medical Science, Center for Medical Science, Fujita Health University,  
7                    Toyoake, Japan

8  
9                    \*Correspondence:

10                   **Hideo Hagihara**

11                   Division of Systems Medical Science, Center for Medical Science, Fujita Health University, 1-98  
12                   Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.

13                   Tel: +81-562-93-9383; Fax: +81-562-93-5382; E-mail: h-hagi@fujita-hu.ac.jp

14                   ORCID ID: 0000-0001-9602-9518

15                   **Tsuyoshi Miyakawa**

16                   Division of Systems Medical Science, Center for Medical Science, Fujita Health University, 1-98  
17                   Dengakugakubo, Kutsukake-cho, Toyoake, Aichi 470-1192, Japan.

18                   Tel: +81-562-93-9376; Fax: +81-562-93-5382; E-mail: miyakawa@fujita-hu.ac.jp

19                   ORCID ID: 0000-0003-0137-8200

20 **Abstract**

21 **Background:** Altered brain energy metabolism is implicated in Alzheimer’s disease (AD). Limited and  
22 conflicting studies on brain pH changes, indicative of metabolic alterations associated with neural  
23 activity, warrant a comprehensive investigation into their relevance in this neurodegenerative  
24 condition. Furthermore, the relationship between these pH changes and established AD  
25 neuropathological evaluations, such as Braak staging, remains unexplored.

26 **Methods:** We conducted quantitative meta-analyses on postmortem brain and cerebrospinal fluid  
27 pH in patients with AD and non-AD controls, using publicly available demographic data. We  
28 collected raw pH data from studies in the NCBI GEO, PubMed, and Google Scholar databases.

29 **Results:** Our analysis of 17 datasets (457 patients and 315 controls) using a random-effects model  
30 showed a significant decrease in brain and cerebrospinal fluid pH in patients compared to controls  
31 (Hedges’  $g = -0.54$ ,  $p < 0.0001$ ). This decrease remained significant after considering postmortem  
32 interval, age at death, and sex. Notably, pH levels were negatively correlated with Braak stage,  
33 indicated by the random-effects model of correlation coefficients from 15 datasets (292 patients and  
34 159 controls) (adjusted  $r = -0.26$ ,  $p < 0.0001$ ). Furthermore, brain pH enhanced the discriminative  
35 power of the *APOE*ε4 allele, the most prevalent risk gene for AD, in distinguishing patients from  
36 controls in a meta-analysis of four combined datasets (95 patients and 87 controls).

37 **Conclusions:** The significant decrease in brain pH in AD underlines its potential role in disease  
38 progression and diagnosis. This decrease, potentially reflecting neural hyperexcitation, could  
39 enhance our understanding of neurodegenerative pathology and aid in developing diagnostic  
40 strategies.

41 **Key words:** Alzheimer’s disease, brain pH, Braak stage, systematic review, meta-analysis

## 42 **Introduction**

43 Alzheimer's disease (AD) is a prevalent neurodegenerative disease worldwide, posing one of the  
44 most significant health burdens of the 21<sup>st</sup> century (Prince et al., 2015; Scheltens et al., 2016).  
45 Genetic studies have demonstrated that AD has a high heritability, with multiple genetic factors  
46 contributing to the disease. Over 50 risk loci have been associated with AD at a genome-wide  
47 significance level (Sims et al., 2020). Among them, point mutations leading to the  $\epsilon 4$  allele of  
48 apolipoprotein E (*APOE*) are known to be the most potent genetic risk factor for the common  
49 sporadic and late-onset forms of AD, as well as influencing rarer familial and early-onset forms of  
50 the disease (Saunders et al., 1993; Belloy et al., 2019; Sims et al., 2020; Serrano-Pozo et al., 2021).  
51 While the *APOE* gene is suggested to have no association with disease progression (Wilkosz et al.,  
52 2010), many other factors can influence the development and progression of pathophysiological  
53 changes in the brains of individuals with AD. In particular, pH in the brain could be significant in  
54 the pathophysiology of AD, as low pH has been reported to exacerbate the aggregation of the  
55 amyloid- $\beta$  peptide and hyperphosphorylation of Tau protein, key pathological hallmarks of the  
56 disease (Atwood et al., 1998; Basurto-Islas et al., 2013; Decker et al., 2021). To date, studies of pH  
57 changes in the brain of AD have been limited and the results are inconsistent. One postmortem  
58 study involving four available datasets has reported a decrease in brain and cerebrospinal fluid  
59 (CSF) pH in patients with AD compared to control subjects in each dataset (Decker et al., 2021).  
60 The results of the magnetic resonance spectroscopy (MRS) studies were inconsistent: a decrease  
61 (Lyros et al., 2020), no significant change (Mandal et al., 2012), and an increase (Mecheri et al.,  
62 1997; Rijpma et al., 2018) in pH have been observed in the hippocampus and other regions of the  
63 brain of patients with AD. Furthermore, no study has yet elucidated the relationship between brain

64 pH and the progression of AD, particularly in the context of Braak staging – a well-established  
65 neuropathological method for AD diagnosis based on neurofibrillary tangles (Braak and Braak,  
66 1991).

67

68 Decreased brain pH has been consistently suggested in schizophrenia and bipolar disorder by  
69 meta-analysis of MRS and postmortem studies (Dogan et al., 2018; Hagihara et al., 2018; Pruett and  
70 Meador-Woodruff, 2020). We recently found similar phenomenon in major depressive disorder in a  
71 systematic review and meta-analysis of postmortem studies (Hagihara and Miyakawa, submitted). A  
72 decrease in brain pH is suggested to be associated with an increase in lactate level under these  
73 psychiatric disorders (Prabakaran et al., 2004; Stork and Renshaw, 2005; Halim et al., 2008), which  
74 could be due to metabolic changes resulting from mitochondrial dysfunction and/or increased  
75 glycolysis due to neuronal hyperexcitation. An increase in brain (Mullins et al., 2018; Hirata et al.,  
76 2024) and CSF (Liguori et al., 2015, 2016) lactate levels has been observed in patients with AD  
77 compared to control subjects, suggesting common metabolic alterations and neuronal  
78 hyperexcitability across such psychiatric and neurodegenerative disorders.

79

80 In view of the limited studies and contradictory results regarding pH changes in AD, in this study  
81 we conducted a systematic review and quantitative meta-analyses of pH in the postmortem brain  
82 and CSF in patients with AD compared to non-AD control subjects, utilizing publicly available  
83 demographic data. Furthermore, we conducted meta-analyses to investigate the association between  
84 pH and disease progression assessed by the Braak staging and the discriminative ability of brain pH  
85 in distinguishing patients with AD from control subjects.

86

## 87 **Methods**

### 88 **Ethics approval and consent to participate**

89 This study was performed based on publicly available data and no separate ethical approval was  
90 required.

91

### 92 **Identification and selection of eligible datasets of postmortem brain and CSF pH**

93 Datasets were selected based on the availability of raw pH data of individual subjects. We searched  
94 the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus database  
95 (GEO), PubMed, and Google Scholar for studies reporting individual pH data with key words  
96 “Alzheimer’s disease”, “brain pH”, “postmortem” and “Braak”. The dataset searches followed the  
97 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (Page et al., 2021)  
98 and were conducted on October 2023. The workflow of the selection of pH datasets is shown in Fig.  
99 1. Articles were screened first based on their titles, followed by a subsequent evaluation of their  
100 abstracts to determine eligibility for full-text review. For records identified in PubMed and Google  
101 Scholar, inclusion criteria were of studies involving human AD versus non-AD control comparisons  
102 (CON) using postmortem brain or CSF samples and the availability of full text and individual raw  
103 data. To minimize the inclusion of overlapping samples across different studies, we attempted to  
104 identify and remove duplicated samples from studies that used partially overlapping samples from  
105 the same source, and then combined the remaining data into a single dataset. If conditions other  
106 than CON or AD were present within the study, they were excluded from the current analysis. We  
107 also obtained the accompanying demographic information from the identified datasets (i.e.,

108 postmortem interval (PMI), age at death, sex, Braak stage, and *APOE* genotype). In the dataset of  
109 Ueberham 2006, Braak stage labeled as V–VI was treated as 5.5. In the datasets that provided ABC  
110 score, scores 1, 2, and 3 in category "B" (representing Braak stage) were treated as stages 1.5, 3.5,  
111 and 5.5, respectively, as score 1 encompasses Braak stage I or II, score 2 corresponds to stage III or  
112 IV, and score 3 to stages V or VI (Montine et al., 2012). A score of 0 indicates the absence of  
113 neurofibrillary pathology. In the dataset of Gabitto 2023, age labeled as 90+ was considered as 90.

114

### 115 **Data analysis**

116 Effect size, measured by Hedges'  $g$ , and standard error was calculated within each dataset, and the  
117 random effects model was applied using the function `metagen` in the R package `meta` (version 6.5-0).  
118 Analysis of covariance (ANCOVA) were performed using the GLM procedure in SAS (version  
119 3.81; SAS Institute Inc., Cary, NC, USA). For a correlation analysis, we calculated the Pearson  
120 correlation coefficient within each dataset. To estimate the standard error of the correlation  
121 coefficient, we used the formula:  $SE_r = (1-r^2)/(n-2)^{1/2}$ , where  $r$  is the Pearson correlation coefficient,  
122 and  $n$  is the number of samples in the correlation. We then applied the random effects model to the  
123 correlation coefficient ( $r$ ) and its standard error ( $SE_r$ ), as described above. Z-score transformation, a  
124 method of data normalization for direct comparison between different conditions, was applied to  
125 each pH value using individual subject data within each dataset according to the following formula:  
126  $Z\text{-score} = (\text{value}_P - \text{mean value}_{P1\dots Pn})/\text{standard deviation}_{P1\dots Pn}$ , where  $P$  is any pH or lactate and  
127  $P1\dots Pn$  represent the aggregate measure of all pH values. We conducted the receiver operating  
128 characteristics (ROC) curve analysis to evaluate the discriminative ability of the *APOE* $\epsilon 4$  status, pH  
129 level, and their combination in identifying patients with AD from control subjects, as assessed by

130 the numerical gains in the area under the curve (AUC). The ROC analyses were performed using  
131 GraphPad Prism 8 (version 8.4.2; GraphPad Software, San Diego, CA). For ROC analyses, z-score  
132 transformation, a conventional method for data normalization to enable direct comparison between  
133 different conditions, was applied to pH values within each dataset, given their heterogeneity across  
134 datasets. Multiple logistic regression analyses were applied to the z-score of pH level, *APOE* $\epsilon$ 4  
135 status (yes = 1, i.e.  $\epsilon$ 3/ $\epsilon$ 4 and  $\epsilon$ 4/ $\epsilon$ 4; no = 0), and their combination, respectively.

136

## 137 **Results**

### 138 **Search results**

139 Following screening the 250 and 67 records retrieved from the searches in PubMed and Google  
140 Scholar, and the NCBI GEO database, 20 and 4 studies were identified to report raw pH data,  
141 respectively (Fig. 1). After removing duplicates, a total of 19 datasets were processed for the  
142 meta-analysis: 1) 17 datasets for comparison analysis of pH between patients with AD and control  
143 subjects (Fig. 2); 2) 15 for correlation analysis between pH and Braak stage (Fig. 3); and 3) seven  
144 for comparison analysis of pH between *APOE* $\epsilon$ 4 carriers and non-*APOE* $\epsilon$ 4 carriers (Supplementary  
145 Fig. 3) and ROC curve analysis (Fig. 4). A summary of the datasets, which contains information on  
146 pH, PMI, age at death, and sex, is presented in Supplementary Table 1. The source and references of  
147 the datasets used are also included in Supplementary Table 1. The raw data analyzed in this study  
148 are provided in Supplementary Table 2.

149

### 150 **Decreased brain and CSF pH in AD**

151 In the 17 datasets obtained (Supplementary Table 1), six showed a significant decrease in pH in

152 patients with AD compared to the corresponding controls within each dataset (GSE44771,  $p = 3.51$   
153  $\times 10^{-7}$ ; GSE84422,  $p = 0.044$ ; Guennewig 2021,  $p = 0.0016$ ; Haytural 2021,  $p = 0.015$ ; Jacobs 2006,  
154  $p = 0.021$ ; Passila 2019, 2020,  $p = 0.033$ ; two-tailed unpaired t-test). The others showed no  
155 significant difference in pH between patients and controls. No datasets showed a significant  
156 increase in pH. Funnel plot and Egger's test showed no evidence of publication bias for the 17  
157 datasets ( $t = -0.89$ ,  $p = 0.39$ ; Supplementary Fig. 1). The meta-analysis using the random effects  
158 model revealed a significant decrease in pH in patients with AD compared control subjects (Hedges'  
159  $g = -0.54$ ,  $z = -4.97$ ,  $p < 0.0001$ , 95% CI = [-0.75; -0.33]) (Fig. 2). The  $I^2$  test showed high  
160 heterogeneity suggesting significant differences between datasets ( $I^2 = 65\%$ ,  $p < 0.01$ ). In a two-way  
161 ANCOVA, with the dataset and diagnosis as the main factors, the effect of diagnosis remained  
162 significant (mean square (MS) = 2.25,  $F = 23.78$ ,  $p < 0.0001$ ), while no significant effects were  
163 observed for PMI (MS = 0.12,  $F = 1.24$ ,  $p = 0.26$ ), age at death (MS = 0.35,  $F = 3.71$ ,  $p = 0.055$ ), or  
164 sex (MS = 0.29,  $F = 3.06$ ,  $p = 0.081$ ). The effect of dataset was significant (MS = 1.31,  $F = 13.85$ ,  $p$   
165  $< 0.0001$ ). These results suggest that, while the pH varied between datasets, it was decreased in  
166 patients with AD compared to controls, independently of the covariates examined.

167

### 168 **A decrease in pH is associated with progressive brain pathological changes**

169 The current assessment of the severity of pathological changes in AD is mainly based on the Braak  
170 staging, where stages I–II represent clinically silent cases, stages III–IV incipient AD, and stages  
171 V–VI fully developed AD (Braak and Braak, 1991). We then examined the relationship between  
172 brain pH levels and the Braak stage. In the 15 datasets obtained (Supplementary Table 1), four  
173 showed a significant negative correlation between pH levels and Braak stage in each dataset



174 (GSE84422,  $r = -0.24$ ,  $p = 0.015$ ; Passila 2019, 2020,  $r = -0.50$ ,  $p = 0.018$ ; Jacobs 2006,  $r = -0.49$ ,  $p$   
175  $= 0.0064$ ; Haytural 2021,  $r = -0.64$ ,  $p = 0.010$ ). The others showed no significant correlation within  
176 datasets. The meta-analysis, employing a random effects model, revealed a significant negative  
177 correlation between pH levels and Braak stage (adjusted  $r = -0.26$ ,  $p < 0.0001$ , 95% CI = [-0.38;  
178 -0.13]) (Fig. 3). This negative correlation was corroborated by linear regression analysis on 15  
179 combined datasets, standardized using z-score normalization, which showed a modest but  
180 significant relationship ( $r = -0.20$ ,  $p = 1.37 \times 10^{-5}$ ; Supplementary Fig. 2). These results suggest that  
181 lower pH levels are associated with higher severity of the disease.

182

183 The brain pH also showed significant negative correlations with other pathological and clinical  
184 rating scores, including clinical dementia rating ( $r = -0.22$ ,  $p = 0.026$ ), average neuritic plaque  
185 density ( $r = -0.25$ ,  $p = 0.0095$ ), sum of Consortium to Establish a Registry for Alzheimer's Disease  
186 (CERAD) rating scores in multiple brain regions ( $r = -0.34$ ,  $p = 0.0004$ ), and sum of neurofibrillary  
187 tangles density in multiple brain regions ( $r = -0.24$ ,  $p = 0.014$ ) (Supplementary Fig. 3). These results  
188 support the idea that lower pH levels are associated with higher severity of the disease.

189

### 190 **Brain pH improves discriminative ability of *APOE* $\epsilon$ 4 status in AD**

191 The  $\epsilon$ 4 allele of apolipoprotein E (*APOE*) is the strongest genetic risk factor for sporadic AD  
192 (Belloy et al., 2019). While *APOE* $\epsilon$ 4 status did not affect brain pH level either in patients with AD  
193 or control subjects (Supplementary Fig. 4), it exhibited a significant discriminative ability in  
194 identifying patients from controls, as determined by the ROC curve analysis using seven datasets  
195 consisting of 264 subjects (Fig. 4, Supplementary Table 1). The ROC AUC values of the

196 single-predictor model were 0.66 for *APOE*ε4 status (95% CI: 0.60–0.73,  $p < 0.0001$ ) and 0.62 for  
197 the pH level (95% CI: 0.55–0.69,  $p = 0.0008$ ). When the pH level was added to the *APOE*ε4 status,  
198 the ROC AUC value increased to 0.72 (95% CI: 0.66–0.78,  $p < 0.0001$ ;  $p$  for difference 0.0075)  
199 (Fig. 4). The discriminative accuracy of *APOE*ε4 status was improved by the combination with the  
200 pH level, suggesting that these two variables have a complementary value.

201

## 202 **Discussion**

203 The present study suggested that brain pH is decreased in patients with AD compared to control  
204 subjects even when PMI, age, and sex were considered as potential confounding factors. We  
205 recently showed that a decrease in brain pH in AD can be estimated through the analysis of gene  
206 expression patterns (Hagihara et al., 2023), which aligns with the findings of this study.  
207 Furthermore, the increased levels of brain lactate in patients with AD provide additional support for  
208 the observed decrease in pH.

209

210 A decrease in brain pH has been linked to an increase in lactate levels in schizophrenia and bipolar  
211 disorder (Prabakaran et al., 2004; Stork and Renshaw, 2005; Halim et al., 2008). An increase in  
212 lactate levels is considered indicative of metabolic alterations resulting from mitochondrial  
213 dysfunction and/or increased glycolysis due to neuronal hyperexcitation. Lactate is thought to be a  
214 relatively strong acid due to its ability to almost completely dissociate into  $H^+$  ions and lactate  
215 anions at cellular pH (Siesjö, 1985). Indeed, hyperexcitation in certain neurons and/or neural  
216 circuits has been suggested in the etiology of AD (Busche and Konnerth, 2016; Murano et al., 2019;  
217 Maestú et al., 2021). Furthermore, an increase in brain (Mullins et al., 2018; Hirata et al., 2024) and

218 CSF (Liguori et al., 2015, 2016) lactate levels has been observed in patients with AD compared to  
219 control subjects. Neuronal hyperexcitation (Palop et al., 2007; You et al., 2017) and increased brain  
220 lactate and decreased brain pH levels (Hagihara et al., 2024) have been observed in a well-known  
221 mouse model of AD harboring the human amyloid precursor protein (APP) mutant allele that is  
222 linked to familial AD. At a cellular level, glycolysis and subsequent lactate release are stimulated by  
223 the uptake of the neurotransmitter glutamate in astrocytes following neuronal activation, as  
224 demonstrated in an *in vitro* study (Pellerin and Magistretti, 1994). Astrocytes are considered to  
225 prefer lactate production in the brain. A shift towards excitation would increase energy demands in  
226 neurons, potentially prompting astrocytes to elevate lactate production, which in turn could lower  
227 brain pH. Indeed, increased lactate levels, accompanied by astrocyte activation, have been observed  
228 in the brains of individuals of AD (Hirata et al., 2024). Therefore, the observed decrease in brain pH  
229 may be attributed to elevated lactate levels induced by neuronal hyperexcitation in AD.  
230 Activity-dependent acidosis has been suggested to suppress neuronal activity in animal models of  
231 neonatal febrile seizures and is proposed as an intrinsic mechanism for the self-termination of  
232 seizures (Chesler and Kaila, 1992; Schuchmann et al., 2006; Pavlov et al., 2013). Further research is  
233 needed to determine whether a decrease in brain pH is related to such compensatory mechanisms in  
234 chronic degenerative diseases.

235

236 We found a negative correlation between brain pH and Braak stage, suggesting a lower brain pH as  
237 the disease course progresses. Braak staging of AD is based on the propagation of tau  
238 neurofibrillary tangles in the brain and the stage of tau pathology is associated with cognitive  
239 impairment (Braak and Braak, 1991). It is hypothesized that soluble amyloid- $\beta$  oligomers cause

240 hyperphosphorylation of tau and the accumulation of neurofibrillary tangle (Zheng et al., 2002);  
241 however, the local relationship between amyloid and tau was restricted in several brain regions  
242 (Iaccarino et al., 2018), suggesting additional causes for tau accumulation. Interestingly, neuronal  
243 hyperexcitation has been suggested to enhance tau protein translation in neurons, which may lead  
244 to the pathological accumulation of tau in soma and dendrite of neuronal cells (Kobayashi et al.,  
245 2017, 2019). Therefore, a decrease in pH and the accumulation of tau may occur in parallel due to  
246 neuronal hyperexcitation. Furthermore, acidic conditions could increase the abnormal  
247 hyperphosphorylation of tau protein *in vitro* (Basurto-Islas et al., 2013). These potential direct and  
248 indirect relationships between pH and tau pathology could contribute to the observed negative  
249 correlation between pH and Braak stage. Brain pH may serve as a surrogate for Braak stage.

250

251 We found that brain pH significantly improved discriminative accuracy of *APOE* $\epsilon$ 4 status in  
252 distinguishing patients with AD from control subjects. A previous *in vivo* MRS study showed that  
253 brain pH improved diagnostic accuracy of brain metabolite (i.e., N-acetylaspartate/creatine ratio)  
254 for AD (Lyros et al., 2020). While brain pH alone exhibited relatively low (AUC of 0.62 in this  
255 study) to moderate (AUC of 0.81 in (Lyros et al., 2020)) accuracy for distinguishing patients with  
256 AD from control subject, combining it – measured in CSF or by MRS – with other markers could  
257 be a valuable biological strategy to assist in the diagnosis of AD.

258

259 Regarding potential bias in this study, the Egger's regression test on the funnel plot showed no  
260 significant publication bias across datasets analyzed. Additionally, relying on demographic rather  
261 than primary outcome data may minimize typical outcome bias.

262

263 A significant limitation of this study may involve the lack of consideration for other potential  
264 confounding factors affecting postmortem brain pH than age at death, PMI, and sex. Factors prior to  
265 death, or agonal states, and the cause and manner of death can influence postmortem brain pH  
266 through alterations in blood oxygenation, brain perfusion, and biochemical content (Lewis, 2002;  
267 Tomita et al., 2004). If patients with AD experienced prolonged agonal conditions compared to  
268 controls in the datasets used, we cannot rule out the possibility that the observed decrease in pH was  
269 influenced by such factors. It is technically difficult to exclude the influence of potential  
270 confounding factors in human studies. In this circumstance, studies in animal models can be useful  
271 alternatives to confirm whether changes in brain pH are involved in the pathophysiology of  
272 neuropsychiatric disorders, as they are essentially exempt from such confounding factors. In our  
273 recent study, we showed that APP transgenic AD model mice exhibited a decrease in brain pH  
274 compared to corresponding control mice (Hagihara et al., 2024), supporting the notion that this  
275 phenomenon is intrinsically related to pathophysiology of AD rather than mere an artifact.

276

277 In conclusion, this study suggested that postmortem brain and CSF pH is decreased in patients with  
278 AD compared to control subjects. The decrease in pH may occur independent of having *APOE* $\epsilon$ 4  
279 genotype, the most prominent genetic risk of AD. Neuronal hyperexcitation may lead to the  
280 decrease in pH, which may be exacerbated in the disease course. It remains undetermined whether  
281 such a decrease in pH is associated with either beneficial or detrimental effects on psychiatric  
282 conditions, which is required to be addressed in the future studies.

283

284 **Acknowledgements**

285 The authors thank Yoko Kagami and Harumi Mitsuya for their administrative assistance.

286

287 **Funding**

288 This work was supported by MEXT Promotion of Distinctive Joint Research Center Program Grant

289 Number JPMXP0618217663 and JSPS KAKENHI Grant Number JP20H00522.

290

291 **Data availability**

292 The raw data analyzed in this study are provided in Supplementary Table 2.

293

294 **Author contributions**

295 HH and TM conceived this study. HH performed data search, analyzed data, and drafted the

296 manuscript. All authors contributed to revising the manuscript and approved its final version.

297

298 **Conflict of Interest**

299 The authors have nothing to disclose.

300

301 **Additional information**

302 The review was not registered elsewhere. The review protocol was not prepared.

303 **References**

- 304 Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NME, Romano DM, Hartshorn MA, Tanzi  
305 RE, Bush AI (1998) Dramatic Aggregation of Alzheimer A $\beta$  by Cu(II) Is Induced by  
306 Conditions Representing Physiological Acidosis. *J Biol Chem* 273:12817–12826.
- 307 Basurto-Islas G, Grundke-Iqbal I, Tung YC, Liu F, Iqbal K (2013) Activation of Asparaginyl  
308 Endopeptidase Leads to Tau Hyperphosphorylation in Alzheimer Disease. *J Biol Chem*  
309 288:17495–17507.
- 310 Belloy ME, Napolioni V, Greicius MD (2019) A Quarter Century of APOE and Alzheimer's  
311 Disease: Progress to Date and the Path Forward. *Neuron* 101:820–838.
- 312 Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta*  
313 *Neuropathol (Berl)* 82:239–259.
- 314 Busche MA, Konnerth A (2016) Impairments of neural circuit function in Alzheimer's disease.  
315 *Philos Trans R Soc B Biol Sci* 371:20150429.
- 316 Chesler M, Kaila K (1992) Modulation of pH by neuronal activity. *Trends Neurosci* 15:396–402.
- 317 Decker Y, Németh E, Schomburg R, Chemla A, Fülöp L, Menger MD, Liu Y, Fassbender K (2021)  
318 Decreased pH in the aging brain and Alzheimer's disease. *Neurobiol Aging* 101:40–49.
- 319 Dogan AE, Yuksel C, Du F, Chouinard V-A, Öngür D (2018) Brain lactate and pH in schizophrenia  
320 and bipolar disorder: a systematic review of findings from magnetic resonance studies.  
321 *Neuropsychopharmacology* 43:1681–1690.
- 322 Hagihara H et al. (2024) Large-scale animal model study uncovers altered brain pH and lactate  
323 levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive  
324 impairment. *eLife* 12:RP89376.
- 325 Hagihara H, Catts VS, Katayama Y, Shoji H, Takagi T, Huang FL, Nakao A, Mori Y, Huang K-P,  
326 Ishii S, Graef IA, Nakayama KI, Shannon Weickert C, Miyakawa T (2018) Decreased brain  
327 pH as a shared endophenotype of psychiatric disorders. *Neuropsychopharmacology*  
328 43:459–468.

- 329 Hagihara H, Murano T, Miyakawa T (2023) The gene expression patterns as surrogate indices of pH  
330 in the brain. *Front Psychiatry* 14:1151480.
- 331 Halim ND, Lipska BK, Hyde TM, Deep-Soboslay A, Saylor EM, Herman M, Thakar J, Verma A,  
332 Kleinman JE (2008) Increased lactate levels and reduced pH in postmortem brains of  
333 schizophrenics: medication confounds. *J Neurosci Methods* 169:208–213.
- 334 Hirata K et al. (2024) Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer’s  
335 Disease. *Ann Neurol* 95:104–115.
- 336 Iaccarino L, Tammewar G, Ayakta N, Baker SL, Bejanin A, Boxer AL, Gorno-Tempini ML, Janabi  
337 M, Kramer JH, Lazaris A, Lockhart SN, Miller BL, Miller ZA, O’Neil JP, Ossenkoppele R,  
338 Rosen HJ, Schonhaut DR, Jagust WJ, Rabinovici GD (2018) Local and distant relationships  
339 between amyloid, tau and neurodegeneration in Alzheimer’s Disease. *NeuroImage Clin*  
340 17:452–464.
- 341 Kobayashi S, Tanaka T, Soeda Y, Almeida OFX, Takashima A (2017) Local Somatodendritic  
342 Translation and Hyperphosphorylation of Tau Protein Triggered by AMPA and NMDA  
343 Receptor Stimulation. *eBioMedicine* 20:120–126.
- 344 Kobayashi S, Tanaka T, Soeda Y, Takashima A (2019) Enhanced Tau Protein Translation by  
345 Hyper-Excitation. *Front Aging Neurosci* 11:322.
- 346 Lewis DA (2002) The Human Brain Revisited: Opportunities and Challenges in Postmortem  
347 Studies of Psychiatric Disorders. *Neuropsychopharmacology* 26:143–154.
- 348 Liguori C, Chiaravalloti A, Sancesario G, Stefani A, Sancesario GM, Mercuri NB, Schillaci O,  
349 Pierantozzi M (2016) Cerebrospinal fluid lactate levels and brain [18F]FDG PET  
350 hypometabolism within the default mode network in Alzheimer’s disease. *Eur J Nucl Med*  
351 *Mol Imaging* 43:2040–2049.
- 352 Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG, Pierantozzi M (2015) CSF  
353 lactate levels,  $\tau$  proteins, cognitive decline: a dynamic relationship in Alzheimer’s disease. *J*  
354 *Neurol Neurosurg Psychiatry* 86:655–659.
- 355 Lyros E, Ragoschke-Schumm A, Kostopoulos P, Sehr A, Backens M, Kalampokini S, Decker Y,



- 356 Lesmeister M, Liu Y, Reith W, Fassbender K (2020) Normal brain aging and Alzheimer's  
357 disease are associated with lower cerebral pH: an in vivo histidine 1H-MR spectroscopy  
358 study. *Neurobiol Aging* 87:60–69.
- 359 Maestú F, de Haan W, Busche MA, DeFelipe J (2021) Neuronal excitation/inhibition imbalance:  
360 core element of a translational perspective on Alzheimer pathophysiology. *Ageing Res Rev*  
361 69:101372.
- 362 Mandal PK, Akolkar H, Tripathi M (2012) Mapping of hippocampal pH and neurochemicals from  
363 in vivo multi-voxel 31P study in healthy normal young male/female, mild cognitive  
364 impairment, and Alzheimer's disease. *J Alzheimers Dis JAD* 31 Suppl 3:S75-86.
- 365 Mecheri G, Marie-Cardine M, Sappey-Marinier D, Bonmartin H, Albrand G, Ferry G,  
366 Coppard-Meyer N, Courpron P (1997) In vivo hippocampal (31)P NMR metabolites in  
367 Alzheimer's disease and ageing. *Eur Psychiatry J Assoc Eur Psychiatr* 12:140–148.
- 368 Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP,  
369 Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Trojanowski JQ, Vinters HV,  
370 Hyman BT (2012) National Institute on Aging–Alzheimer's Association guidelines for the  
371 neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathol*  
372 (Berl) 123:1–11.
- 373 Mullins R, Reiter D, Kapogiannis D (2018) Magnetic resonance spectroscopy reveals abnormalities  
374 of glucose metabolism in the Alzheimer's brain. *Ann Clin Transl Neurol* 5:262–272.
- 375 Murano T, Hagihara H, Tajinda K, Matsumoto M, Miyakawa T (2019) Transcriptomic immaturity  
376 inducible by neural hyperexcitation is shared by multiple neuropsychiatric disorders.  
377 *Commun Biol* 2:32.
- 378 Page MJ et al. (2021) The PRISMA 2020 statement: An updated guideline for reporting systematic  
379 reviews. *Int J Surg* 88:105906.
- 380 Palop JJ, Chin J, Roberson ED, Wang J, Thwin MT, Bien-Ly N, Yoo J, Ho KO, Yu G-Q, Kreitzer A,  
381 Finkbeiner S, Noebels JL, Mucke L (2007) Aberrant excitatory neuronal activity and  
382 compensatory remodeling of inhibitory hippocampal circuits in mouse models of  
383 Alzheimer's disease. *Neuron* 55:697–711.

- 384 Pavlov I, Kaila K, Kullmann DM, Miles R (2013) Cortical inhibition, pH and cell excitability in  
385 epilepsy: what are optimal targets for antiepileptic interventions?: Cortical inhibition, pH  
386 and cell excitability in epilepsy. *J Physiol* 591:765–774.
- 387 Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a  
388 mechanism coupling neuronal activity to glucose utilization. *Proc Natl Acad Sci*  
389 91:10625–10629.
- 390 Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT-J, Griffin JL, Wayland M, Freeman T,  
391 Dudbridge F, Lilley KS, Karp NA, Hester S, Tkachev D, Mimmack ML, Yolken RH,  
392 Webster MJ, Torrey EF, Bahn S (2004) Mitochondrial dysfunction in schizophrenia:  
393 evidence for compromised brain metabolism and oxidative stress. *Mol Psychiatry*  
394 9:684–697.
- 395 Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M (2015) World Alzheimer Report 2015.  
396 The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends.  
397 *Alzheimer’s Dis Int* hal-03495438.
- 398 Pruett BS, Meador-Woodruff JH (2020) Evidence for altered energy metabolism, increased lactate,  
399 and decreased pH in schizophrenia brain: A focused review and meta-analysis of human  
400 postmortem and magnetic resonance spectroscopy studies. *Schizophr Res* 223:29–42.
- 401 Rijpma A, van der Graaf M, Meulenbroek O, Olde Rikkert MGM, Heerschap A (2018) Altered  
402 brain high-energy phosphate metabolism in mild Alzheimer’s disease: A 3-dimensional 31P  
403 MR spectroscopic imaging study. *NeuroImage Clin* 18:254–261.
- 404 Saunders AM, Roses AD, Pericak-Vance MA, Dole KC, Strittmatter WJ, Schmechel DE,  
405 Szymanski MH, McCown N, Manwaring MG, Schmader K, Breitner JCS, Goldgaber D,  
406 Benson MD, Goldfarb L, Brown WT (1993) Apolipoprotein E  $\epsilon$ 4 allele distributions in  
407 late-onset Alzheimer’s disease and in other amyloid-forming diseases. *The Lancet*  
408 342:710–711.
- 409 Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM  
410 (2016) Alzheimer’s disease. *The Lancet* 388:505–517.
- 411 Schuchmann S, Schmitz D, Rivera C, Vanhatalo S, Salmen B, Mackie K, Sipilä ST, Voipio J, Kaila

- 412 K (2006) Experimental febrile seizures are precipitated by a hyperthermia-induced  
413 respiratory alkalosis. *Nat Med* 12:817–823.
- 414 Serrano-Pozo A, Das S, Hyman BT (2021) APOE and Alzheimer’s disease: advances in genetics,  
415 pathophysiology, and therapeutic approaches. *Lancet Neurol* 20:68–80.
- 416 Siesjö BK (1985) Acid-Base Homeostasis in the Brain: Physiology, Chemistry, and Neurochemical  
417 Pathology. In: *Progress in Brain Research* (K. Kogure K-AH BK Siesjö and FA Welsh, ed),  
418 pp 121–154 *Molecular Mechanisms of Ischemic Brain Damage*. Elsevier.
- 419 Sims R, Hill M, Williams J (2020) The multiplex model of the genetics of Alzheimer’s disease. *Nat*  
420 *Neurosci* 23:311–322.
- 421 Stork C, Renshaw PF (2005) Mitochondrial dysfunction in bipolar disorder: evidence from  
422 magnetic resonance spectroscopy research. *Mol Psychiatry* 10:900–919.
- 423 Tomita H, Vawter MP, Walsh DM, Evans SJ, Choudary PV, Li J, Overman KM, Atz ME, Myers RM,  
424 Jones EG, Watson SJ, Akil H, Bunney Jr. WE (2004) Effect of agonal and postmortem  
425 factors on gene expression profile: quality control in microarray analyses of postmortem  
426 human brain. *Biol Psychiatry* 55:346–352.
- 427 Wilkosz PA, Seltman HJ, Devlin B, Weamer EA, Lopez OL, DeKosky ST, Sweet RA (2010)  
428 Trajectories of cognitive decline in Alzheimer’s disease. *Int Psychogeriatr* 22:281–290.
- 429 You JC, Muralidharan K, Park JW, Petrof I, Pyfer MS, Corbett BF, LaFrancois JJ, Zheng Y, Zhang  
430 X, Mohila CA, Yoshor D, Rissman RA, Nestler EJ, Scharfman HE, Chin J (2017)  
431 Epigenetic suppression of hippocampal calbindin-D28k by  $\Delta$ FosB drives seizure-related  
432 cognitive deficits. *Nat Med* 23:1377–1383.
- 433 Zheng W-H, Bastianetto S, Mennicken F, Ma W, Kar S (2002) Amyloid  $\beta$  peptide induces tau  
434 phosphorylation and loss of cholinergic neurons in rat primary septal cultures.  
435 *Neuroscience* 115:201–211.

436

437 **Figure legends**

438 **Figure 1. Workflow of the selection of postmortem brain and CSF pH datasets.**

439

440 **Figure 2. Decreased pH in the postmortem brain and CSF of patients with AD.** Forest plot of  
441 meta-analysis comparing postmortem brain and CSF pH between patients with AD and non-AD  
442 control subjects. 95% CI, 95% confidence interval; SE, standard error; SMD, standardized mean  
443 difference.

444

445 **Figure 3. Negative correlation between brain pH and Braak stages.** Forest plot of meta-analysis  
446 of correlation between brain pH and Braak stages. 95% CI, 95% confidence interval; CC,  
447 correlation coefficient; SE, standard error.

448

449 **Figure 4. Brain pH level increases discriminative accuracy of *APOE* $\epsilon$ 4 status for AD.** ROC  
450 curves for brain pH level, *APOE* $\epsilon$ 4 status, and their combination to assess the accuracy of prediction  
451 of AD against controls. AUC, area under the curve.

452

453 **Supplementary information**

454 **Supplementary Table 1. Summary of datasets used in this study**

455

456 **Supplementary Table 2. Raw data analyzed in this study**

457

458 **Supplementary Figure 1. Funnel plot of the included datasets.** Each plot represents a dataset. SE,  
459 standard error; SMD, standardized mean difference.

460

461 **Supplementary Figure 2. Scatter plot depicting the negative correlation between pH (z-score)**  
462 **and Braak stages.** A z-score was calculated for each subject within the dataset to standardize pH  
463 measurements. Each dot represents the data for an individual subject.  $r$ , Pearson correlation  
464 coefficient.

465

466 **Supplementary Figure 3. Significant correlation between a decrease in brain pH and an**  
467 **increase in disease severity.** Data of GSE84422 was analyzed. Scatter plot of correlation between  
468 brain pH and clinical dementia rating (A), average neuritic plaque density (B), sum of Consortium  
469 to Establish a Registry for Alzheimer's Disease (CERAD) rating scores in multiple brain regions (C),  
470 and sum of neurofibrillary tangles density in multiple brain regions (D). The solid line indicates the  
471 regression line, and the dashed line indicates the 95% confidence interval.  $r$ , Pearson correlation  
472 coefficient.

473

474 **Supplementary Figure 4. No significant effect of *APOE* $\epsilon$ 4 status on brain pH.** Forest plot of  
475 meta-analysis comparing postmortem brain pH between *APOE* $\epsilon$ 4 carriers and non-carriers in  
476 control subjects (A; Hedges'  $g = -0.40$ , 95% CI = [-0.80; 0.0056],  $p = 0.053$ ) and patients with AD  
477 (B; Hedges'  $g = 0.046$ , 95% CI = [-0.31; 0.40],  $p = 0.80$ ). 95% CI, 95% confidence interval; SE,  
478 standard error; SMD, standardized mean difference.

Identification

Records identified through database searching: PubMed and Google Scholar (n = 250)

Records screened  
(n = 250)

Records excluded  
- no human AD studies (n = 42)  
- no peer-reviewed paper (n = 86)  
- no full-text available (n = 21)  
- no individual pH data reported (n = 81)

Records screened  
(n = 20)

Duplicated records removed  
(n = 4)

Datasets after duplicates removed (n = 15):

- 1) datasets including pH data of both AD and CON (n = 13)
- 2) datasets including both pH and Braak score data (n = 13)
- 3) datasets including both pH and *APOE* status data (n = 6)

Screening

Records identified in Gene Expression Omnibus database  
(n = 67)

Records screened  
(n = 67)

Records excluded  
- no human AD studies  
or no individual pH  
data available (n = 63)


Records after screening (n = 4):


- 1) datasets including pH data of both AD and CON (n = 4)
- 2) datasets including both pH and Braak score data (n = 2)
- 3) datasets including both pH and *APOE* status data (n = 1)

Included


Datasets included in quantitative synthesis (meta-analysis) (n = 19):

- 1) comparison analysis between AD and CON (n = 17)
- 2) correlation analysis between pH and Braak score (n = 15)
- 3) comparison analysis between *APOE*ε4 carriers and non-*APOE*ε4 carriers and ROC curve analysis (n = 7)









- *APOEε4* + pH (AUC = 0.72,  $p < 0.0001$ )
- .... *APOEε4* (AUC = 0.66,  $p < 0.0001$ )
- pH (AUC = 0.62,  $p = 0.0008$ )